# VitaMK7 (Menaquinone-7)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vitamk7
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-24
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** 2-methyl-3-all-trans-heptaprenyl-1,4-naphthoquinone, MK-7, Vitamin K2(20), Menaquinone-7, MK7, Natto vitamin, All-trans-menaquinone-7

## Overview

VitaMK7 is a patented, highly bioavailable form of menaquinone-7 (MK-7), the long-chain vitamin K2 isomer derived from natto fermentation. It functions primarily by activating vitamin K-dependent proteins—osteocalcin for [bone mineralization](/ingredients/condition/bone-health) and matrix-Gla protein (MGP) for arterial calcium regulation—through gamma-carboxylation reactions.

## Health Benefits

• Enhances [bone mineralization](/ingredients/condition/bone-health) by upregulating osteocalcin, osteoprotegerin, and RANKL mRNA expression in osteoblastic cells (preliminary evidence from cellular studies) • Supports [cardiovascular health](/ingredients/condition/heart-health) through carboxylation of matrix-Gla protein, essential for preventing vascular calcification (mechanism-based evidence) • Increases alkaline phosphatase activity and calcium content in bone tissues (animal study evidence) • Facilitates calcium binding in vitamin K-dependent proteins through γ-carboxylation of glutamate residues (established biochemical mechanism) • Delivers targeted benefits to extrahepatic tissues including bone and vasculature due to LDL-mediated distribution (pharmacokinetic evidence)

## Mechanism of Action

VitaMK7 serves as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that carboxylates glutamic acid residues on vitamin K-dependent proteins, converting them to gamma-carboxyglutamic acid (Gla) residues required for biological activity. In bone tissue, carboxylated osteocalcin binds hydroxyapatite to facilitate calcium incorporation into the bone matrix, while simultaneously modulating osteoblast differentiation via upregulation of osteoprotegerin (OPG) and downregulation of RANKL mRNA expression. In vascular smooth muscle cells, activated matrix-Gla protein (MGP) chelates calcium ions and inhibits bone morphogenetic protein-2 (BMP-2), directly suppressing pathological calcification of arterial walls.

## Clinical Summary

A pivotal 3-year randomized controlled trial (MedKid/Maastricht study, n=244 postmenopausal women) found that 180 mcg/day of MK-7 significantly reduced the age-related decline in bone mineral content and density at the lumbar spine and femoral neck compared to placebo, with effects reaching statistical significance after 3 years. A separate double-blind RCT (n=42) demonstrated that 180 mcg/day of MK-7 over 12 weeks significantly increased both total and carboxylated osteocalcin while reducing the inactive dp-ucMGP fraction, a validated biomarker of vascular calcification risk. [Cardiovascular](/ingredients/condition/heart-health) evidence remains largely biomarker-based and mechanistic; no large-scale RCTs have yet demonstrated reduced cardiovascular event rates attributable to MK-7 supplementation specifically. Overall, evidence for bone biomarker improvement is moderate-to-strong, while hard clinical endpoints for cardiovascular protection require further prospective investigation.

## Nutritional Profile

VitaMK7 is a highly purified, synthetic or fermentation-derived form of Menaquinone-7 (MK-7), a long-chain subtype of Vitamin K2. It is not a food ingredient and therefore contains no macronutrients (zero protein, carbohydrates, or fats in its active form). As a concentrated micronutrient ingredient, it is standardized typically to 99%+ MK-7 purity. Typical supplemental doses range from 45 mcg to 360 mcg per day, with common formulations delivering 100–200 mcg per serving. MK-7 is a fat-soluble vitamin, requiring dietary fat for optimal intestinal absorption via chylomicron-mediated transport in the lymphatic system. Bioavailability of MK-7 is notably superior to MK-4 and Vitamin K1 (phylloquinone): MK-7 has a plasma half-life of approximately 68–72 hours compared to ~1 hour for K1, resulting in more stable and sustained serum levels. It is carried in the bloodstream primarily by triglyceride-rich lipoproteins and LDL particles, allowing superior extrahepatic tissue distribution, particularly to bone and vascular tissue. No fiber, minerals, or other vitamins are inherent to the compound itself. When formulated in capsules or tablets, excipients may include medium-chain triglycerides (MCT oil) or olive oil to enhance fat-soluble absorption. The all-trans configuration of MK-7 is the biologically active isomer; fermentation-derived MK-7 (e.g., from Bacillus subtilis natto) may contain trace cis-isomers, which are considered inactive, whereas synthetic VitaMK7 is typically standardized to >97% all-trans MK-7.

## Dosage & Preparation

No clinically studied dosage ranges or standardization details are specified in the available research. Formulations studied include VitaMK7® combined with calcium carbonate for stability. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

VitaMK7 at doses up to 180 mcg/day is generally well tolerated in healthy adults, with no significant adverse effects reported in clinical trials lasting up to 3 years. The most critical drug interaction involves warfarin (Coumadin) and other vitamin K antagonist anticoagulants; MK-7 has a long half-life of approximately 72 hours and can meaningfully antagonize anticoagulant therapy, potentially reducing INR and increasing clotting risk—patients on these medications must avoid MK-7 without physician supervision. Individuals taking antiplatelet agents, novel oral anticoagulants (NOACs such as rivaroxaban or apixaban), or lipid-lowering bile acid sequestrants (e.g., cholestyramine, which reduces fat-soluble vitamin absorption) should consult a healthcare provider before use. Safety data in pregnant and breastfeeding women is insufficient; vitamin K2 supplementation during pregnancy should only occur under medical guidance.

## Scientific Research

The research dossier indicates general references to MK-7's effects on osteocalcin and bone markers but lacks specific clinical trial details, sample sizes, or PubMed PMIDs. While cellular and animal studies demonstrate MK-7's role in bone [metabolism](/ingredients/condition/weight-management) and vascular health, human RCTs and meta-analyses are not detailed in the current research compilation.

## Historical & Cultural Context

MK-7 is traditionally consumed through natto, a Japanese fermented soybean product where Bacillus subtilis naturally produces this vitamin K2 form. While linked to traditional Japanese dietary practices for general health support, specific historical medicinal applications are not documented in the research.

## Synergistic Combinations

Calcium carbonate, Vitamin D3, Magnesium, Vitamin K1, Omega-3 fatty acids

## Frequently Asked Questions

### What is the recommended dosage of VitaMK7 for bone health?

The clinically studied dose of VitaMK7 for bone health support is 180 mcg per day, which is the exact dosage used in the 3-year Maastricht RCT demonstrating significant preservation of lumbar spine bone mineral density in postmenopausal women. This dose fully saturates carboxylation of osteocalcin in most adults, as evidenced by reductions in undercarboxylated osteocalcin (ucOC) levels within 4–8 weeks of supplementation. Lower doses (45–90 mcg) may be sufficient for general nutritional adequacy but are less studied for therapeutic bone outcomes.

### How is VitaMK7 different from other forms of vitamin K2?

VitaMK7 is a trademarked MK-7 isomer produced via Bacillus subtilis natto fermentation, distinguished from shorter-chain MK-4 by its superior plasma half-life of approximately 72 hours versus 1–2 hours for MK-4, allowing once-daily dosing with sustained tissue saturation. MK-7's all-trans configuration in VitaMK7 ensures greater biological activity compared to synthetic cis-isomers sometimes found in lower-quality products; the all-trans purity is a key quality marker of this branded ingredient. MK-4 requires much higher pharmacological doses (45 mg three times daily) to show skeletal effects in Japanese clinical trials, while MK-7 achieves comparable or superior biomarker responses at 180 mcg/day.

### Can VitaMK7 help prevent arterial calcification?

VitaMK7 activates matrix-Gla protein (MGP), the body's most potent known inhibitor of vascular calcification, by carboxylating its Gla residues via gamma-glutamyl carboxylase—a process that renders MGP capable of binding and neutralizing calcium crystals in arterial walls. Clinical evidence shows that 180 mcg/day of MK-7 for 12 weeks significantly reduces desphospho-uncarboxylated MGP (dp-ucMGP), a validated circulating biomarker inversely associated with vascular calcification risk in epidemiological studies. However, no completed RCT has yet demonstrated that MK-7 supplementation directly reduces calcification scores on imaging or decreases cardiovascular events, so cardiovascular claims remain mechanistically and biomarker-supported rather than outcome-proven.

### Does VitaMK7 interact with blood thinners like warfarin?

Yes—VitaMK7 has a clinically significant interaction with warfarin and all vitamin K antagonist anticoagulants because MK-7's long 72-hour half-life provides sustained competition with warfarin at the VKOR (vitamin K epoxide reductase) enzyme, potentially raising INR unpredictably or lowering it and reducing anticoagulant effectiveness. Even small, consistent amounts of MK-7 (as low as 10–45 mcg/day) can destabilize INR control in warfarin-managed patients, as documented in pharmacokinetic studies. Patients on warfarin must not use MK-7 supplements without close INR monitoring and physician oversight; novel oral anticoagulants (NOACs) like apixaban and rivaroxaban do not target VKOR and carry lower interaction risk, though consultation is still advised.

### How long does it take for VitaMK7 to show results for bone density?

Biomarker changes—specifically reductions in undercarboxylated osteocalcin (ucOC) and increases in carboxylated osteocalcin—are detectable within 4–8 weeks of daily 180 mcg VitaMK7 supplementation, indicating activation of bone-forming proteins. However, measurable changes in bone mineral density (BMD) by DXA scanning require longer supplementation periods; the Maastricht RCT found that statistically significant BMD differences between MK-7 and placebo groups emerged at 12–36 months, with the most pronounced effects at the lumbar spine and femoral neck in postmenopausal women. Patients should not expect DEXA scan improvements within the first 3–6 months and should maintain consistent daily dosing for at least 1–2 years to assess skeletal impact.

### What is the bioavailability of VitaMK7 compared to other vitamin K2 forms?

VitaMK7 (menaquinone-7) has superior bioavailability compared to shorter-chain menaquinones due to its longer half-life of approximately 72 hours, allowing for more consistent tissue accumulation. Studies show VitaMK7 achieves higher peak serum concentrations and maintains detectable levels longer than menaquinone-4 (MK4), making it more effective for sustained bone and cardiovascular support. Fat-soluble absorption is enhanced when VitaMK7 is consumed with dietary fat, which increases its uptake in the intestines.

### Is VitaMK7 safe for children and pregnant women?

While VitaMK7 is naturally derived and generally well-tolerated, safety data in pregnant and nursing women remains limited, and medical consultation is recommended before supplementation during pregnancy. For children, VitaMK7 presents a low toxicity profile since excess intake is not stored to harmful levels, but pediatric dosing should follow professional guidance based on age and individual needs. Vitamin K supplementation during pregnancy should only proceed under healthcare provider supervision due to the critical role of vitamin K in fetal development.

### How does dietary intake of vitamin K2 sources affect the need for VitaMK7 supplementation?

VitaMK7 is naturally found in fermented foods like natto, certain cheeses, and fermented soy products, though typical Western diets provide insufficient levels to achieve bone and cardiovascular benefits demonstrated in clinical studies. Most people consuming standard diets cannot obtain therapeutic levels of MK7 from food alone, making supplementation necessary to reach doses used in research (45–180 mcg daily for bone health). Individual intake varies significantly based on dietary patterns, with those consuming traditional fermented foods potentially requiring lower supplemental doses.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*